Table 1 Baseline parameters of 120 patients
All patients (N = 120) | HBeAg-positive (n = 67) | HBeAg-negative (n = 53) | |||||
|---|---|---|---|---|---|---|---|
TDF/TAF (n = 43) | ETV (n = 24) | p value | TDF/TAF (n = 17) | ETV (n = 36) | p value | ||
Age (years) | 42.9 (34.0–55.0) | 38.0 (31.0–52.0) | 43.8 (38.3–56.0) | 0.136 | 55.0 (41.2–62.1) | 40.9 (35.8–50.0) | 0.004 |
Number of male patients | 76 (63.3%) | 25/43 (58.1%) | 16/24 (66.7%) | 0.604 | 11/17 (64.7%) | 29/36 (80.6%) | 0.002 |
HBcrAg (log U/mL) | 3.64 (2.24–5.23) | 5.23 (4.36–5.63) | 4.87 (3.40–5.34) | 0.066 | 2.03 (1.35–2.70) | 2.25 (1.43–2.99) | 0.517 |
Percentage of patients with undetectable HBcrAg* | 0% | 0% | 0% | N/A | 0% | 0% | NA |
ALT | 73 (53–138) | 79 (58–144) | 89 (49–304) | 0.646 | 57 (46–79) | 72 (54–153) | 0.099 |
Percentage of patients with elevated ALT | 103/120 (85.8%) | 37/43 (86.0%) | 21/24 (87.5%) | 1.00 | 16/17 (94.1%) | 29/36 (80.6%) | 0.412 |
Percentage of patients with cirrhosis | 7/120 (5.8%) | 0/43 (0%) | 0/24 (0%) | N/A | 0/17 (0%) | 7/36 (19.4%) | 0.082 |